{"id":"NCT03349710","sponsor":"Bristol-Myers Squibb","briefTitle":"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-15","primaryCompletion":"2019-10-14","completion":"2019-10-14","firstPosted":"2017-11-21","resultsPosted":"2021-08-09","lastUpdate":"2021-08-09"},"enrollment":74,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]},{"type":"DRUG","name":"Cetuximab","otherNames":["Erbitux"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"RADIATION","name":"Radiotherapy","otherNames":[]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"EXPERIMENTAL"},{"label":"Arm C","type":"EXPERIMENTAL"},{"label":"Arm D","type":"EXPERIMENTAL"}],"summary":"This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin","primaryOutcome":{"measure":"Number of Participants With an Adverse Event (AE)","timeFrame":"30 Days","effectByArm":[{"arm":"Arm A (Cohort 1)","deltaMin":12,"sd":null},{"arm":"Arm B (Cohort 1)","deltaMin":10,"sd":null},{"arm":"Arm C (Cohort 2)","deltaMin":27,"sd":null},{"arm":"Arm D (Cohort 2)","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":55,"countries":["United States","France","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":12},"commonTop":["Nausea","Constipation","Radiation skin injury","Dry mouth","Anaemia"]}}